Vertex Secures FDA Approval for New Cystic Fibrosis Drug AlyftrekZacks Investment Research • 12/23/24
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish AnalystBenzinga • 12/23/24
Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?The Motley Fool • 12/22/24
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered StockInvestors Business Daily • 12/20/24
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic FibrosisBusiness Wire • 12/20/24
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive VariantsBusiness Wire • 12/20/24
Shareholders that lost money on Vertex Pharmaceuticals Incorporated (VRTX) should contact Levi & Korsinsky about Securities Fraud Investigation - VRTXAccesswire • 12/20/24
Vertex Pharmaceuticals Incorporated Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VRTXAccesswire • 12/20/24
VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as PlaceboZacks Investment Research • 12/20/24
Vertex Pharmaceuticals Inc. (VRTX) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's InvestigationAccesswire • 12/20/24
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?Benzinga • 12/19/24
Vertex Pharmaceuticals Inc. (VRTX) Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the FirmGlobeNewsWire • 12/19/24
Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back PainInvestors Business Daily • 12/19/24
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.Investors Business Daily • 12/19/24
Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral RadiculopathyBusiness Wire • 12/19/24
Why Vertex Pharmaceuticals (VRTX) Outpaced the Stock Market TodayZacks Investment Research • 12/16/24